文献速递哮喘

Tezepelumab在重度未控制哮喘中的疗效:PATHWAY与NAVIGATOR试验汇总分析

Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

该汇总分析纳入PATHWAY和NAVIGATOR两项随机双盲安慰剂对照试验中接受tezepelumab 210 mg或安慰剂每4周皮下注射52周的重度未控制哮喘患者,共1334例。结果显示tezepelumab总体降低年化哮喘加重率60%(率比0.40,95%CI 0.34-0.48),且在多个临床相关亚组中均观察到有临床意义的加重减少,不良事件发生率与安慰剂相似。

要点

  • tezepelumab总体降低年化哮喘加重率60%,率比0.40(95%CI 0.34-0.48)。
  • 在2型高和2型低疾病(多种定义)患者中均观察到有临床意义的加重减少。
  • tezepelumab减少加重相关住院或急诊就诊,不良事件发生率与安慰剂相似。

核心结论

  • tezepelumab在重度未控制哮喘患者中,跨临床相关亚组,有临床意义地减少加重并改善其他结局。

研究设计与样本

  • 汇总分析基于PATHWAY(2b期)和NAVIGATOR(3期)两项设计相似的随机双盲安慰剂对照试验。
  • 纳入重度未控制哮喘患者(PATHWAY 18-75岁;NAVIGATOR 12-80岁),接受tezepelumab 210 mg或安慰剂皮下注射每4周一次,共52周。
  • 共纳入1334例患者(tezepelumab组n=665;安慰剂组n=669)。

主要发现

  • 总体人群中,tezepelumab较安慰剂降低年化哮喘加重率60%(率比0.40,95%CI 0.34-0.48)。
  • 在2型高和2型低疾病(多种定义)的tezepelumab治疗患者中均观察到有临床意义的加重减少。
  • tezepelumab减少加重相关住院或急诊就诊,并在总体和各亚组中改善次要结局。
  • 治疗组间不良事件发生率相似。

临床怎么用

  • 对于重度未控制哮喘患者,tezepelumab 210 mg每4周皮下注射可显著降低加重率,且不受2型炎症生物标志物水平限制。
  • tezepelumab可减少加重相关住院或急诊就诊,安全性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Tezepelumab reduced exacerbations in patients with severe, uncontrolled asthma across a range of baseline blood eosinophil counts and fractional exhaled nitric oxide levels, and irrespective of allergy status, in the phase 2b PATHWAY (Study to Evaluate the Efficacy and Safety of MEDI9929 [AMG 157] in Adult Subjects With Inadequately Controlled, Severe Asthma; NCT02054130) and phase 3 NAVIGATOR (Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma; NCT03347279) trials. Objectives: To examine the efficacy and safety of tezepelumab in additional clinically relevant subgroups using pooled data from PATHWAY and NAVIGATOR. Methods: PATHWAY and NAVIGATOR were randomized, double-blind, placebo-controlled trials with similar designs. This pooled analysis included patients with severe, uncontrolled asthma (PATHWAY, 18-75 years old; NAVIGATOR, 12-80 years old) who received tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. The annualized asthma exacerbation rate over 52 weeks and secondary outcomes were calculated in the overall population and in subgroups defined by inflammatory biomarker levels or clinical characteristics. Measurements and Main Results: Overall, 1,334 patients were included (tezepelumab, n = 665; placebo, n = 669). Tezepelumab reduced the annualized asthma exacerbation rate versus placebo by 60% (rate ratio, 0.40 [95% confidence interval, 0.34-0.48]) in the overall population, and clinically meaningful reductions in exacerbations were observed in tezepelumab-treated patients with type 2-high and type 2-low disease by multiple definitions. Tezepelumab reduced exacerbation-related hospitalization or emergency department visits and improved secondary outcomes compared with placebo overall and across subgroups. The incidence of adverse events was similar between treatment groups. Conclusions: Tezepelumab resulted in clinically meaningful reductions in exacerbations and improvements in other outcomes in patients with severe, uncontrolled asthma, across clinically relevant subgroups. Clinical trials registered with www.clinicaltrials.gov (NCT02054130 [PATHWAY], NCT03347279 [NAVIGATOR]).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Corren, Menzies-Gow, Chupp, et al. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. Am J Respir Crit Care Med. 2023. PMID: 37015033. doi:10.1164/rccm.202210-2005OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。